Loading data for BTAI — first visit, this takes a few seconds.

BioXcel Therapeutics, Inc. (BTAI)

NasdaqCM: BTAI · Real-Time Price · USD

0.07

-0.05 (-41.67%)

At close: Sep 04, 2026, 8:00 PM

0.04

-43.03%

After-hours: 7:59 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	0.16
Market Cap	2.31M
Revenue (ttm)	742K
Net Income (ttm)	-70.9M
	0.19
	-2.58
	n/a
	-0.03
P/B (ttm)	-0.02
P/S (ttm)	3.12
Earnings Date	Mar 26, 2026

Ask	0.12
Volume	47,480,718
Avg. Volume (20D)	6,209,709
Open	0.09
Previous Close	0.12
Day's Range	0.07 - 0.09
52-Week Range	0.07 - 3.95
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About BTAI

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501...

Sector Healthcare

IPO Date Mar 8, 2018

Employees 29

Stock Exchange NasdaqCM

Ticker Symbol BTAI

Website https://www.bioxceltherapeutics.com

Full Company Profile

Financial Performance

In 2025, BioXcel Therapeutics's revenue was 642K, a decrease of -71.67% compared to the previous year's 2.27M. Earnings were -69.9M, an increase of 17.28%.

Financial Statements

Earnings Surprise

BioXcel Therapeutics has released their quarterly earnings on Aug 13, 2026:

Revenue of $182K misses estimates by $0, with 51.67% YoY growth.
EPS of -0.49 exceeds estimates by 0.09, with 67.33% YoY growth.

Next Earnings Release

BioXcel Therapeutics, Inc. is scheduled to release its earnings on Mar 26, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

4 days ago · Insider Monkey

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therap...

1 week ago · Zacks

Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid

TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.

1 week ago · Pharmaceutical Technology

Teva makes stalking horse bid for BioXcel assets

The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501.

1 week ago · Hospital Management

Teva Pharmaceuticals to acquire BioXcel assets for up to $125m

The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501.

1 week ago · Simply Wall St.

What Is Teva Pharmaceutical Industries (TEVA) Gaining From This Bankruptcy Drug Deal?

Teva Pharmaceutical Industries (NYSE:TEVA) agreed to acquire BioXcel Therapeutics' dexmedetomidine sublingual film for at-home treatment of agitation in schizophrenia and bipolar disorder through a ba...

Page 1 of 2

BioXcel Therapeutics, Inc. (BTAI)